Victoza liraglutide: Additional Phase III data

Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Victoza liraglutide ( NN2211) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Desc...